SCHEMBL3266677

SCHEMBL3266677

CC(C)(C)OC(=O)NN=Cc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.76
MIF P14174 2/20 0.75
RAB9A P51151 9/20 0.73
SMN1; SMN2 Q16637 8/20 0.73
NPC1 O15118 7/20 0.73
RECQL P46063 1/20 0.73
KDM4E B2RXH2 3/20 0.64
KMT2A Q03164 6/20 0.60
LMNA P02545 3/20 0.60
ALDH1A1 P00352 3/20 0.60
MEN1 O00255 4/20 0.59
MAPK1 P28482 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
TP53 P04637 1/20 0.54
ESRRG P62508 1/20 0.52
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12979794 1.00 MAPT (0.76) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL6423387 1.00 MAPT (0.76) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL6444624 0.91 MAPT (0.72) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL23241901 0.89 MAPT (0.74) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL23241902 0.89 MAPT (0.74) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL5765848 0.86 MAPT (1.00) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL6444643 0.86 MIF (1.00) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL6444640 0.86 MIF (1.00) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL13401232 0.86 MIF (0.78) MAPTMIFRAB9ASMN1; SMN2NPC1
SCHEMBL5767618 0.84 MAPT (0.71) MAPTMIFRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115368378-B Substituted macrocyclic compounds, compositions comprising the same and uses thereof 深圳市塔吉瑞生物医药有限公司 2024-11-19 CN disclosed
CN-115368378-A Substituted macrocyclic compounds, compositions containing the same and uses thereof 深圳市塔吉瑞生物医药有限公司 2022-11-22 CN disclosed
EP-1506969-B1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS US INC (US) 2010-06-09 EP disclosed
EP-1335908-B1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS LILLY CO ELI (US) 2008-02-13 EP disclosed
EP-1184370-B1 Compounds with growth hormone releasing properties NOVO NORDISK AS (DK) 2005-09-14 EP disclosed
EP-1506969-A1 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-02-16 EP disclosed
EP-1047709-B1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK AS (DK) 2004-11-03 EP disclosed
US-20040102500-A1 Peroxisome proliferator activated receptor alpha agonists CANO IVAN COLLADO (ES) 2004-05-27 US disclosed
EP-1335908-A2 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS ELI LILLY AND COMPANY (US) 2003-08-20 EP disclosed
WO-2002038553-A2 TRIAZOLE DERIVATIVES AND THEIR USE AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS ELI LILLY AND COMPANY (US) 2002-05-16 WO disclosed
EP-1184370-A2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
US-6274584-B1 PEPTIDE DERIVATIVES; BIOAVAILABILITY; ENZYME RESISTANCE; MILK AND WOOL PRODUCTION NOVO NORDISK A/S (DK) 2001-08-14 US disclosed
EP-1047709-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 2000-11-02 EP disclosed
US-6127354-A FOR TREATMENT OF GROWTH DISORDERS OR TO STIMULATE PRODUCTION OF WOOL OR MILK NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
WO-1999036431-A9 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK AS (DK) 2000-07-27 WO disclosed
US-6083908-A TREATING MEDICAL DISORDERS RESULTING FROM DEFICIENCY IN GROWTH HORMONE NOVO NORDISK A/S (DK) 2000-07-04 US disclosed
WO-1999036431-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-07-22 WO disclosed
US-5922770-A NOVEL COMPOUNDS THAT STIMULATE THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 1999-07-13 US disclosed
EP-0923539-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-06-23 EP disclosed
WO-1998003473-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102500-A1 Peroxisome proliferator activated receptor alpha agonists PPARG, PPARA, PPARD MAPT 4786/4885MIF 4854/4885RAB9A 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.